Latest immunotherapies Stories
AMSTERDAM, February 11, 2014 /PRNewswire/ -- - SynCo's live microbial track record, GMP scale-up and commercial manufacturing capabilities will facilitate the
DURHAM, N.C., Jan.
Inovio develops DNA-based immune booster (IL-33) that enhances T-cell responses and generates effective CD8 mediated tumor regression BLUE BELL, Pa., Jan.
Juno CEO Hans Bishop to Address JP Morgan's 32nd Annual Healthcare Conference SEATTLE, Jan.
Published in the Journal for ImmunoTherapy of Cancer, review offers recommendations for manufacturing, pre-clinical studies, and clinical trial designs of cancer immunotherapies Milwaukee,